Nature Physics, ISSN 1745-2473, 11/2017, Volume 13, Issue 11, pp. 1074 - 1078
A central issue in the quest to understand the superconductivity in cuprates is the nature and origin of the pseudogap state, which harbours anomalous...
Journal Article
PHYSICAL REVIEW LETTERS, ISSN 0031-9007, 05/2016, Volume 116, Issue 21
A hidden order that emerges in the frustrated pyrochlore Tb2+xTi2-xO7+y with T-c = 0.53 K is studied using specific heat, magnetization, and neutron scattering...
ANTIFERROMAGNET TB2TI2O7 | SUPERCONDUCTIVITY | EXCITATIONS | SPIN-LIQUID-STATE | PHYSICS, MULTIDISCIPLINARY | GAUGE-INVARIANCE | ICE | MAGNETS
ANTIFERROMAGNET TB2TI2O7 | SUPERCONDUCTIVITY | EXCITATIONS | SPIN-LIQUID-STATE | PHYSICS, MULTIDISCIPLINARY | GAUGE-INVARIANCE | ICE | MAGNETS
Journal Article
Physical review letters, 05/2016, Volume 116, Issue 21, p. 217201
A hidden order that emerges in the frustrated pyrochlore Tb_{2+x}Ti_{2-x}O_{7+y} with T_{c}=0.53 K is studied using specific heat, magnetization, and neutron...
Journal Article
Physical Review Letters, ISSN 0031-9007, 05/2016, Volume 116, Issue 21
Journal Article
Journal of Human Genetics, ISSN 1434-5161, 04/2013, Volume 58, Issue 4, pp. 195 - 201
The relationship between Y-chromosome single-nucleotide polymorphisms (SNPs) registered in the Japanese SNP (JSNP) database (http://snp.ims.u-tokyo.ac.jp) and...
Haplogroup | JSNP database | Y-chromosomal haplogroup tree | Japanese | Non-recombining portions of Y | Y chromosome | MARKER | HAPLOTYPES | IDENTIFICATION | AINU | ORIGINS | POLYMORPHISMS | haplogroup | GENETICS & HEREDITY | GENE CONVERSION | non-recombining portions of Y | BINARY HAPLOGROUPS | Chromosomes, Human, Y - genetics | Haplotypes | Genetics, Population | Humans | Japan | Asian Continental Ancestry Group - genetics | Polymerase Chain Reaction | DNA Primers - metabolism | Genotype | Polymorphism, Single Nucleotide | Mutation | DNA Primers - chemistry
Haplogroup | JSNP database | Y-chromosomal haplogroup tree | Japanese | Non-recombining portions of Y | Y chromosome | MARKER | HAPLOTYPES | IDENTIFICATION | AINU | ORIGINS | POLYMORPHISMS | haplogroup | GENETICS & HEREDITY | GENE CONVERSION | non-recombining portions of Y | BINARY HAPLOGROUPS | Chromosomes, Human, Y - genetics | Haplotypes | Genetics, Population | Humans | Japan | Asian Continental Ancestry Group - genetics | Polymerase Chain Reaction | DNA Primers - metabolism | Genotype | Polymorphism, Single Nucleotide | Mutation | DNA Primers - chemistry
Journal Article
Physical Review Letters, ISSN 0031-9007, 05/2016, Volume 116, Issue 21
Journal Article
Japanese Journal of Applied Physics, ISSN 0021-4922, 12/2018, Volume 57, Issue 12, p. 128001
We proposed color-tunable microfluidic electrogenerated chemiluminescence (ECL) cells. A Y-shaped electro-microfluidic device, which consists of two inlet and...
LIGHT-EMITTING-DIODES | DEVICES | SOLUTION ELECTROCHEMILUMINESCENT CELL | PHYSICS, APPLIED | FABRICATION | Organic chemistry | Color | Chemiluminescence | Light emitting | Emitters | Microscopes | Microfluidics | Channels | Electrons
LIGHT-EMITTING-DIODES | DEVICES | SOLUTION ELECTROCHEMILUMINESCENT CELL | PHYSICS, APPLIED | FABRICATION | Organic chemistry | Color | Chemiluminescence | Light emitting | Emitters | Microscopes | Microfluidics | Channels | Electrons
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 08/2015, Volume 5
We previously discovered multiple superconducting phases in the ammoniated Na-doped FeSe material, (NH3)(y)NaxFeSe. To clarify the origin of the multiple...
MULTIDISCIPLINARY SCIENCES
MULTIDISCIPLINARY SCIENCES
Journal Article
The European Physical Journal C: Particles and Fields, ISSN 1434-6052, 2017, Volume 77, Issue 5, pp. 1 - 53
During 2015 the ATLAS experiment recorded $$3.8\,{\mathrm{fb}}^{-1}$$ 3.8 fb - 1 of proton–proton collision data at a centre-of-mass energy of...
PHYSICS, PARTICLES & FIELDS | Collisions (Nuclear physics) | Protons | Data acquisition systems | Physics - High Energy Physics - Experiment | High Energy Physics - Phenomenology | Physics | PARTICLE ACCELERATORS | Regular - Experimental Physics | Fysik | Physical Sciences | Naturvetenskap | Natural Sciences
PHYSICS, PARTICLES & FIELDS | Collisions (Nuclear physics) | Protons | Data acquisition systems | Physics - High Energy Physics - Experiment | High Energy Physics - Phenomenology | Physics | PARTICLE ACCELERATORS | Regular - Experimental Physics | Fysik | Physical Sciences | Naturvetenskap | Natural Sciences
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events...
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article